Raltitrexed

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Raltitrexed
File:Raltitrexed.svg
File:Raltitrexed ball-and-stick.png
Systematic (IUPAC) name
N-[(5-{methyl[(2-methyl-4-oxo-1,4-dihydroquinazolin-6-yl)methyl]amino}-2-thienyl)carbonyl]-L-glutamic acid
Clinical data
AHFS/Drugs.com Micromedex Detailed Consumer Information
Legal status
  • UK: POM (Prescription only)
  • Not available in U.S.
Routes of
administration		 Intravenous
Identifiers
CAS Number 112887-68-0 YesY
ATC code L01BA03 (WHO)
PubChem CID: 104758
IUPHAR/BPS 7403
DrugBank DB00293 YesY
ChemSpider 94568 YesY
UNII FCB9EGG971 YesY
KEGG D01064 YesY
ChEMBL CHEMBL225071 YesY
PDB ligand ID D16 (PDBe, RCSB PDB)
Chemical data
Formula C21H22N4O6S
Molecular mass 458.489 g/mol
  • O=C(c3sc(N(C)Cc2cc1C(=O)\N=C(/Nc1cc2)C)cc3)N[C@H](C(=O)O)CCC(=O)O
  • InChI=1S/C21H22N4O6S/c1-11-22-14-4-3-12(9-13(14)19(28)23-11)10-25(2)17-7-6-16(32-17)20(29)24-15(21(30)31)5-8-18(26)27/h3-4,6-7,9,15H,5,8,10H2,1-2H3,(H,24,29)(H,26,27)(H,30,31)(H,22,23,28)/t15-/m0/s1 YesY
  • Key:IVTVGDXNLFLDRM-HNNXBMFYSA-N YesY
  (verify)

Raltitrexed (Tomudex, TDX, ZD 1694) is an antimetabolite drug used in cancer chemotherapy. It is an inhibitor of thymidylate synthase, and is manufactured by AstraZeneca.[1]

Uses

Used in treatment of colorectal cancer since 1998. It may also be used in the treatment of malignant mesothelioma.[2]

Mechanism of action

Raltitrexed is chemically similar to folic acid and is in the class of chemotherapy drugs called folate antimetabolites, which inhibit one or more of three enzymes that use folate and derivatives as substrates: DHFR, GARFT and thymidylate synthase. Raltitrexed is fully active after polyglutamylation, which allows cellular retention of the drug.

By inhibiting Thymidylate synthase (TS), thus formation of precursor pyrimidine nucleotides, raltitrexed prevents the formation of DNA and RNA, which are required for the growth and survival of both normal cells and cancer cells.

Inhibition of L1210 cell growth in culture IC50 = 9 nM, is one of the strongest antimetabolites in use.

Structure and phase I clinical trial of the precursor drug, CB3717, was described in 1986.[3]

References

  1. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  2. ↑ [1]
  3. ↑ Lua error in package.lua at line 80: module 'strict' not found.


Retrieved from "https://infogalactic.com/w/index.php?title=Raltitrexed&oldid=1326556"